Login / Signup
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
Send us Feedback
Ligand Pharmaceuticals (LGND)
SUMMARY
BULLS
BEARS
DATA CENTRAL
STOCK CHART
BALANCE SHEET
INCOME STMT
CASH FLOW
Key Metrics for LGND as compared to
Top Competitors
Drug Manufacturers - Other
Pharma & Healthcare
All values TTM unless otherwise noted (*)
INDUSTRY METRICS
No data.
Revenue
Net Income
Operating Income
INCOME STATEMENT (
See all
)
Revenue
►
25.0M
AVG
EBITDA
►
-6.78M
AVG
Net Income
►
-4.98M
AVG
Revenue Growth
►
20.6%
AVG
Net Income Growth
►
-99.1%
LOW
Operating Margin
►
-133.7%
AVG
Net Margin
►
-43.7%
AVG
Revenue, Net Income, and Net Margin
Revenue, Gross Profit, and Gross Margin
Operating Income
Ebit
Income Before Taxes
Net Income from Continuing Ops
Interest vs Continuing Income
Interest Coverage
Operating Expenses
Research & Development
SG&A
Amortization & Depreciation
BALANCE SHEET (most recent quarter) (
See all
)
Debt / Equity
►
-13.3
Current Ratio
►
1.13
LOW
Quick Ratio
►
1.13
LOW
Interest Coverage Ratio
►
-41.4
AVG
Book Value Per Share
►
-0.0840
Cash Per Share
►
0.0457
Loading...
STOCK SUMMARY
Open
1.98
Day Range
2.01
-
2.12
52 Week Range
1.63
-
3.21
Volume
320K
Avg Volume (3 mo)
569K
Shares Outstanding
118M
Market Cap
228M
VALUATION
Price to Earnings (P/E)
►
-20.7
Price to Book (P/B)
►
-23.8
Price to Sales (P/S)
►
9.05
AVG
Return on Assets (ROA)
►
-3.6%
AVG
Return on Equity (ROE)
►
-736.7%
VERY LOW
EV/EBITDA
►
-40.8
Dividend Yield
0%
AVG
ANALYST RECOMMENDATIONS
OWNERSHIP
Net Insider Buying 3mo
0%
Net Insider Buying 6mo
-12.2%
Net Insider Buying 1yr
-7.7%
Held by insiders
34.1%
Held by institutions
64.5%
No Sales Breakout Data.